Ocugen, Inc. OCGN
Ocugen, Inc. (Nasdaq: OCGN) is an ophthalmology drug developer. Its lead program, OCU400, is in Phase 3 for Retinitis pigmentosa (RP). Its next catalyst on record is OCU400: Topline Phase 3 data (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: OCU400 — Topline Phase 3 data (Q1 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| OCU400 | Retinitis pigmentosa | gene therapy | Phase 3 |
| OCU410ST | Stargardt disease | gene therapy | Phase 3 |
| OCU410 | Geographic atrophy secondary to dry AMD | gene therapy | Phase 3 |
| OCU200 | Diabetic macular edema, diabetic retinopathy, wet AMD | biologic-other | Phase 1 |
| OCU500 | COVID-19 | vaccine | Phase 1 |
Recent results and decisions
- Nov 4, 2026accepted OCU400 received Provisional Approval and Priority Designation from the Longevity and Regenerative Therapies (LARTA) Board of The Bahamas.
Granted Provisional Approval and Priority Designation from the Longevity and Regenerative Therapies (LARTA) Board of The Bahamas; agreement with local partner, GARM, to manage process; site readiness progressing; LARTA final approval and potential patient enrollment as early as year-end
Filing - Nov 4, 2026started OCU410 dosed first patient in Phase 3 ArMaDa3 trial for geographic atrophy, a 240-subject global study.
Announced the first patient dosed in ArMaDa3, a 240-subject global Phase 3 trial randomizing patients 2:1 to a single subretinal injection of OCU410 or untreated control across the U.S., Canada, and Europe
Filing - Oct 15, 2026approval Bahamas Regulatory Agency provided provisional approval and priority designation for OCU400 under EAP.
Bahamas Regulatory Agency, (LARTA), provided provisional approval and priority designation of OCU400
Filing
14 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 ophthalmology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.